10-K Filing

Oruka Therapeutics, Inc. CIK: 907654 FY 2023

Filing Information

Form Type	10-K
Accession Number	`0000950170-24-009809`
Period End Date	20231231
Filing Date	20240201
Fiscal Year	2023
Fiscal Period	FY
XBRL Instance	abio-20231231_htm.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 59 Income Statement 21 Cash Flow Statement 35 Stockholders Equity 14

Balance Sheet 59 line items

Line Item	Tag	Value	Unit	Period
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$37.43M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$42.45M	USD	Point-in-time
Other current assets	`OtherAssetsCurrent`	$161.00K	USD	Point-in-time
Other current assets	`OtherAssetsCurrent`	$254.00K	USD	Point-in-time
Total current assets	`AssetsCurrent`	$37.59M	USD	Point-in-time
Total current assets	`AssetsCurrent`	$42.70M	USD	Point-in-time
Accrued expenses and other liabilities (related party - $0 and $216 at December 31, 2023 and 2022, respectively)	`OtherAccruedLiabilitiesCurrent`	$175.00K	USD	Point-in-time
Right-of-use asset - operating	`OperatingLeaseRightOfUseAsset`	$343.00K	USD	Point-in-time
Accrued expenses and other liabilities (related party - $0 and $216 at December 31, 2023 and 2022, respectively)	`OtherAccruedLiabilitiesCurrent`	$625.00K	USD	Point-in-time
Right-of-use asset - operating	`OperatingLeaseRightOfUseAsset`	$247.00K	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$25.00K	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$10.00K	USD	Point-in-time
Preferred stock, par value	`PreferredStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Preferred stock, par value	`PreferredStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Other assets	`OtherAssetsNoncurrent`	$18.00K	USD	Point-in-time
Preferred stock, shares authorized	`PreferredStockSharesAuthorized`	5.00M	shares	Point-in-time
Other assets	`OtherAssetsNoncurrent`	$12.00K	USD	Point-in-time
Preferred stock, shares authorized	`PreferredStockSharesAuthorized`	5.00M	shares	Point-in-time
Total assets	`Assets`	$43.09M	USD	Point-in-time
Preferred stock, issued	`PreferredStockSharesIssued`	0.00	shares	Point-in-time
Total assets	`Assets`	$37.86M	USD	Point-in-time
Preferred stock, issued	`PreferredStockSharesIssued`	0.00	shares	Point-in-time
Preferred stock, outstanding	`PreferredStockSharesOutstanding`	0.00	shares	Point-in-time
Preferred stock, outstanding	`PreferredStockSharesOutstanding`	0.00	shares	Point-in-time
Common stock, par value	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Common stock, par value	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	100.00M	shares	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$362.00K	USD	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	100.00M	shares	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$334.00K	USD	Point-in-time
Common stock, shares issued	`CommonStockSharesIssued`	14.50M	shares	Point-in-time
Accrued compensation and employee benefits	`EmployeeRelatedLiabilitiesCurrent`	$100.00K	USD	Point-in-time
Accrued compensation and employee benefits	`EmployeeRelatedLiabilitiesCurrent`	$173.00K	USD	Point-in-time
Common stock, shares issued	`CommonStockSharesIssued`	14.41M	shares	Point-in-time
Accrued expenses and other liabilities (related party - $0 and $216 at December 31, 2023 and 2022, respectively)	`OtherAccruedLiabilitiesCurrent`	$175.00K	USD	Point-in-time
Common stock, shares outstanding	`CommonStockSharesOutstanding`	14.41M	shares	Point-in-time
Common stock, shares outstanding	`CommonStockSharesOutstanding`	14.50M	shares	Point-in-time
Accrued expenses and other liabilities (related party - $0 and $216 at December 31, 2023 and 2022, respectively)	`OtherAccruedLiabilitiesCurrent`	$625.00K	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$637.00K	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$1.13M	USD	Point-in-time
Operating lease liability, net of current portion	`OperatingLeaseLiabilityNoncurrent`	$280.00K	USD	Point-in-time
Operating lease liability, net of current portion	`OperatingLeaseLiabilityNoncurrent`	$204.00K	USD	Point-in-time
Total liabilities	`Liabilities`	$1.41M	USD	Point-in-time
Total liabilities	`Liabilities`	$841.00K	USD	Point-in-time
Commitments and contingencies	`CommitmentsAndContingencies`	-	USD	Point-in-time
Commitments and contingencies	`CommitmentsAndContingencies`	-	USD	Point-in-time
Preferred stock, $0.001 par value; 5 million shares authorized; no shares issued or outstanding at December 31, 2023 and 2022	`PreferredStockValue`	-	USD	Point-in-time
Preferred stock, $0.001 par value; 5 million shares authorized; no shares issued or outstanding at December 31, 2023 and 2022	`PreferredStockValue`	-	USD	Point-in-time
Common stock, $0.001 par value; 100 million shares authorized at December 31, 2023 and 2022; 14,501,143 and 14,410,143 shares issued and outstanding at December 31, 2023 and 2022, respectively	`CommonStockValue`	$14.00K	USD	Point-in-time
Common stock, $0.001 par value; 100 million shares authorized at December 31, 2023 and 2022; 14,501,143 and 14,410,143 shares issued and outstanding at December 31, 2023 and 2022, respectively	`CommonStockValue`	$14.00K	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapitalCommonStock`	$225.75M	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapitalCommonStock`	$225.06M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-188.74M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-183.40M	USD	Point-in-time
Total stockholders equity	`StockholdersEquity`	$37.02M	USD	Point-in-time
Total stockholders equity	`StockholdersEquity`	$51.04M	USD	Point-in-time
Total stockholders equity	`StockholdersEquity`	$41.67M	USD	Point-in-time
Total liabilities and stockholders equity	`LiabilitiesAndStockholdersEquity`	$37.86M	USD	Point-in-time
Total liabilities and stockholders equity	`LiabilitiesAndStockholdersEquity`	$43.09M	USD	Point-in-time

Income Statement 21 line items

Line Item	Tag	Value	Unit	Period
General and administrative	`GeneralAndAdministrativeExpense`	$6.28M	USD	Annual
General and administrative	`GeneralAndAdministrativeExpense`	$5.85M	USD	Annual
Research and development (related party - $(91) and $432 as of the years ended December 31, 2023 and 2022, respectively)	`ResearchAndDevelopmentExpense`	$1.01M	USD	Annual
Research and development (related party - $(91) and $432 as of the years ended December 31, 2023 and 2022, respectively)	`ResearchAndDevelopmentExpense`	$4.75M	USD	Annual
Total costs and expenses	`OperatingExpenses`	$7.30M	USD	Annual
Total costs and expenses	`OperatingExpenses`	$10.60M	USD	Annual
Loss from operations	`OperatingIncomeLoss`	$-7.30M	USD	Annual
Loss from operations	`OperatingIncomeLoss`	$-10.60M	USD	Annual
Interest and other income	`InterestAndOtherIncome`	$675.00K	USD	Annual
Interest and other income	`InterestAndOtherIncome`	$1.96M	USD	Annual
Other loss	`OtherNonoperatingExpense`	$5.00K	USD	Annual
Net loss	`NetIncomeLoss`	$-9.93M	USD	Annual
Net loss	`NetIncomeLoss`	$-5.34M	USD	Annual
Basic	`EarningsPerShareBasic`	$-0.37	USD	Annual
Basic	`EarningsPerShareBasic`	$-0.69	USD	Annual
Diluted	`EarningsPerShareDiluted`	$-0.37	USD	Annual
Diluted	`EarningsPerShareDiluted`	$-0.69	USD	Annual
Basic	`WeightedAverageNumberOfSharesOutstandingBasic`	14.42M	shares	Annual
Basic	`WeightedAverageNumberOfSharesOutstandingBasic`	14.41M	shares	Annual
Diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	14.42M	shares	Annual
Diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	14.41M	shares	Annual

Cash Flow Statement 35 line items

Line Item	Tag	Value	Unit	Period
Net Income (Loss)	`NetIncomeLoss`	$-9.93M	USD	Annual
Net Income (Loss)	`NetIncomeLoss`	$-5.34M	USD	Annual
Depreciation	`DepreciationAndAmortization`	$20.00K	USD	Annual
Depreciation	`DepreciationAndAmortization`	$15.00K	USD	Annual
Amortization of right-of-use asset - operating	`OperatingLeaseRightOfUseAssetAmortizationExpense`	$96.00K	USD	Annual
Amortization of right-of-use asset - operating	`OperatingLeaseRightOfUseAssetAmortizationExpense`	$94.00K	USD	Annual
Share-based compensation	`ShareBasedCompensation`	$556.00K	USD	Annual
Share-based compensation	`ShareBasedCompensation`	$686.00K	USD	Annual
Loss from disposal of property and equipment	`GainLossOnSaleOfPropertyPlantEquipment`	$-5.00K	USD	Annual
Other current assets	`IncreaseDecreaseInOtherCurrentAssets`	$-808.00K	USD	Annual
Other current assets	`IncreaseDecreaseInOtherCurrentAssets`	$-93.00K	USD	Annual
Other assets	`IncreaseDecreaseInOtherNoncurrentAssets`	-	USD	Annual
Other assets	`IncreaseDecreaseInOtherNoncurrentAssets`	$-6.00K	USD	Annual
Accounts payable	`IncreaseDecreaseInAccountsPayable`	$28.00K	USD	Annual
Accounts payable	`IncreaseDecreaseInAccountsPayable`	$-783.00K	USD	Annual
Accrued compensation and employee benefits	`IncreaseDecreaseInEmployeeRelatedLiabilities`	$-752.00K	USD	Annual
Accrued compensation and employee benefits	`IncreaseDecreaseInEmployeeRelatedLiabilities`	$-73.00K	USD	Annual
Accrued expenses and other liabilities	`IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities`	$-526.00K	USD	Annual
Accrued expenses and other liabilities	`IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities`	$-934.00K	USD	Annual
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-10.91M	USD	Annual
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-5.01M	USD	Annual
Purchase of property and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$2.00K	USD	Annual
Purchase of property and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	-	USD	Annual
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-2.00K	USD	Annual
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	-	USD	Annual
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	-	USD	Annual
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	-	USD	Annual
Net increase in cash and cash equivalents	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$-10.91M	USD	Annual
Net increase in cash and cash equivalents	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$-5.01M	USD	Annual
Cash and cash equivalents, beginning of year	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$42.45M	USD	Point-in-time
Cash and cash equivalents, beginning of year	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$53.36M	USD	Point-in-time
Cash and cash equivalents, beginning of year	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$37.43M	USD	Point-in-time
Cash and cash equivalents, end of year	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$42.45M	USD	Point-in-time
Cash and cash equivalents, end of year	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$53.36M	USD	Point-in-time
Cash and cash equivalents, end of year	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$37.43M	USD	Point-in-time

Stockholders Equity 14 line items

Line Item	Tag	Value	Unit	Period
Beginning Balance	`StockholdersEquity`	$37.02M	USD	Point-in-time
Beginning Balance	`StockholdersEquity`	$51.04M	USD	Point-in-time
Beginning Balance	`StockholdersEquity`	$41.67M	USD	Point-in-time
Beginning Balance, shares	`CommonStockSharesOutstanding`	14.41M	shares	Point-in-time
Beginning Balance, shares	`CommonStockSharesOutstanding`	14.50M	shares	Point-in-time
Share-based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$556.00K	USD	Annual
Share-based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$686.00K	USD	Annual
Net Income (Loss)	`NetIncomeLoss`	$-9.93M	USD	Annual
Net Income (Loss)	`NetIncomeLoss`	$-5.34M	USD	Annual
Ending Balance	`StockholdersEquity`	$37.02M	USD	Point-in-time
Ending Balance	`StockholdersEquity`	$51.04M	USD	Point-in-time
Ending Balance	`StockholdersEquity`	$41.67M	USD	Point-in-time
Ending Balance, shares	`CommonStockSharesOutstanding`	14.41M	shares	Point-in-time
Ending Balance, shares	`CommonStockSharesOutstanding`	14.50M	shares	Point-in-time

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.